Induction of cartilage damage by overexpression of T cell interleukin‐17A in experimental arthritis in mice deficient in interleukin‐1
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: To examine the capacity of T cell interleukin‐17A (IL‐17A; referred to hereinafter as IL‐17) to induce cartilage damage during experimental arthritis in the absence of IL‐1. Methods: Local IL‐17 gene transfer was performed in the knee joint of IL‐1–deficient mice and wild‐type controls during streptococcal cell wall (SCW)–induced arthritis. Knee joints were isolated at various time points for histologic analysis of cartilage proteoglycan (PG) depletion. Expression of messenger RNA for inducible nitric oxide synthase, matrix metalloproteinases (MMPs) 3, 9, and 13, and ADAMTS‐4 was determined by quantitative polymerase chain reaction analysis. VDIPEN staining was analyzed to study MMP‐mediated cartilage damage. In addition, systemic anti–IL‐1α/β antibody treatment was performed in mice immunized with type II collagen and injected locally with an adenoviral vector expressing IL‐17 or with control adenovirus. Knee joints were isolated and analyzed for cartilage PG depletion, chondrocyte death, and cartilage surface erosion. Results: During SCW‐induced arthritis, local T cell IL‐17 gene transfer turned this acute, macrophage‐driven joint inflammation into a severe, chronic arthritis accompanied by aggravated cartilage damage. Of high interest, the IL‐1 dependency of cartilage PG depletion was fully abrogated when IL‐17 was locally overexpressed in the joint. Moreover, local IL‐17 gene transfer increased MMP expression without the need for IL‐1, although IL‐1 remained essential for part of the cartilage VDIPEN expression. Furthermore, when IL‐17 was overexpressed in the knee joints of mice with collagen‐induced arthritis, anti–IL‐1 treatment did not reduce the degree of chondrocyte death or cartilage surface erosion. Conclusion: These data show the capacity of IL‐17 to replace the catabolic function of IL‐1 in cartilage damage during experimental arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., & Maslinski, W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2832 · Cited by 580
Schwandner, R., Yamaguchi, K., & Cao, Z. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1233 · Cited by 349
Cited by
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
“Furthermore, direct effector functions of Th17 cells in rheumatoid arthritis have been demonstrated in that RANKL expression on the surface of Th17 cells induces osteoclastogenesis (120–122), promoting cartilage and bone destruction/resorption independently of TNF and IL-1 (123, 124).”
BackgroundIL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
“Furthermore, overexpression of IL-17 in the joints exacerbates disease (85, 87).”
BackgroundSutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
Tesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis.
Choy, E. (2012) · Rheumatology · doi:10.1093/rheumatology/kes113 · Cited by 816
Expanding the effector CD4 T-cell repertoire: the Th17 lineage
Harrington, L. E., Mangan, P. R., & Weaver, C. T. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.03.017 · Cited by 590
Nigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., van Rossum, M. A. J., Cortis, E., Pardeo, M., Miettunen, P. M., Janow, G., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 463
Induction, function and regulation of IL‐17‐producing T cells
Mills, K. H. G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838535 · Cited by 385
Intricacies of TGF-β signaling in Treg and Th17 cell biology
Wang, J., Zhao, X., & Wan, Y. Y. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01036-7 · Cited by 356
IL-17 as a future therapeutic target for rheumatoid arthritis
van den Berg, W. B., & Miossec, P. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.179 · Cited by 317
Self-citationInterleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors
Adamopoulos, I. E., Chao, C.-C., Geissler, R., Laface, D., Blumenschein, W., Iwakura, Y., McClanahan, T., & Bowman, E. P. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2936 · Cited by 307
Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives
Harrell, C. R., Markovic, B. S., Fellabaum, C., Arsenijevic, A., & Volarevic, V. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.099 · Cited by 301
IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?
Lubberts, E. (2008) · Cytokine · doi:10.1016/j.cyto.2007.09.014 · Cited by 289
Self-citation
Metadata
- Authors
- Koenders, M. I., Lubberts, E., Oppers‐Walgreen, B., van den Bersselaar, L., Helsen, M. M., Kolls, J. K., Joosten, L. A. B., & van den Berg, W. B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-03
- Volume
- 52
- Issue
- 3
- Pages
- 975-983
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2104905374
- Cited by
- 92
- References
- 3
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.